Systems biology approaches reveal a specific interferon-inducible signature in HTLV-1 associated myelopathy.

Human T-lymphotropic virus type 1 (HTLV-1) is a retrovirus that persists lifelong in the host. In ∼4% of infected people, HTLV-1 causes a chronic disabling neuroinflammatory disease known as HTLV-1-associated myelopathy/tropical spastic paraparesis (HAM/TSP). The pathogenesis of HAM/TSP is unknown a...

Full description

Saved in:
Bibliographic Details
Main Authors: Sonja Tattermusch, Jason A Skinner, Damien Chaussabel, Jacques Banchereau, Matthew P Berry, Finlay W McNab, Anne O'Garra, Graham P Taylor, Charles R M Bangham
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2012-01-01
Series:PLoS Pathogens
Online Access:https://journals.plos.org/plospathogens/article/file?id=10.1371/journal.ppat.1002480&type=printable
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1850224555477434368
author Sonja Tattermusch
Jason A Skinner
Damien Chaussabel
Jacques Banchereau
Matthew P Berry
Finlay W McNab
Anne O'Garra
Graham P Taylor
Charles R M Bangham
author_facet Sonja Tattermusch
Jason A Skinner
Damien Chaussabel
Jacques Banchereau
Matthew P Berry
Finlay W McNab
Anne O'Garra
Graham P Taylor
Charles R M Bangham
author_sort Sonja Tattermusch
collection DOAJ
description Human T-lymphotropic virus type 1 (HTLV-1) is a retrovirus that persists lifelong in the host. In ∼4% of infected people, HTLV-1 causes a chronic disabling neuroinflammatory disease known as HTLV-1-associated myelopathy/tropical spastic paraparesis (HAM/TSP). The pathogenesis of HAM/TSP is unknown and treatment remains ineffective. We used gene expression microarrays followed by flow cytometric and functional assays to investigate global changes in blood transcriptional profiles of HTLV-1-infected and seronegative individuals. We found that perturbations of the p53 signaling pathway were a hallmark of HTLV-1 infection. In contrast, a subset of interferon (IFN)-stimulated genes was over-expressed in patients with HAM/TSP but not in asymptomatic HTLV-1 carriers or patients with the clinically similar disease multiple sclerosis. The IFN-inducible signature was present in all circulating leukocytes and its intensity correlated with the clinical severity of HAM/TSP. Leukocytes from patients with HAM/TSP were primed to respond strongly to stimulation with exogenous IFN. However, while type I IFN suppressed expression of the HTLV-1 structural protein Gag it failed to suppress the highly immunogenic viral transcriptional transactivator Tax. We conclude that over-expression of a subset of IFN-stimulated genes in chronic HTLV-1 infection does not constitute an efficient host response but instead contributes to the development of HAM/TSP.
format Article
id doaj-art-9568bf840c1c48c092a25eeccf3a9c12
institution OA Journals
issn 1553-7366
1553-7374
language English
publishDate 2012-01-01
publisher Public Library of Science (PLoS)
record_format Article
series PLoS Pathogens
spelling doaj-art-9568bf840c1c48c092a25eeccf3a9c122025-08-20T02:05:35ZengPublic Library of Science (PLoS)PLoS Pathogens1553-73661553-73742012-01-0181e100248010.1371/journal.ppat.1002480Systems biology approaches reveal a specific interferon-inducible signature in HTLV-1 associated myelopathy.Sonja TattermuschJason A SkinnerDamien ChaussabelJacques BanchereauMatthew P BerryFinlay W McNabAnne O'GarraGraham P TaylorCharles R M BanghamHuman T-lymphotropic virus type 1 (HTLV-1) is a retrovirus that persists lifelong in the host. In ∼4% of infected people, HTLV-1 causes a chronic disabling neuroinflammatory disease known as HTLV-1-associated myelopathy/tropical spastic paraparesis (HAM/TSP). The pathogenesis of HAM/TSP is unknown and treatment remains ineffective. We used gene expression microarrays followed by flow cytometric and functional assays to investigate global changes in blood transcriptional profiles of HTLV-1-infected and seronegative individuals. We found that perturbations of the p53 signaling pathway were a hallmark of HTLV-1 infection. In contrast, a subset of interferon (IFN)-stimulated genes was over-expressed in patients with HAM/TSP but not in asymptomatic HTLV-1 carriers or patients with the clinically similar disease multiple sclerosis. The IFN-inducible signature was present in all circulating leukocytes and its intensity correlated with the clinical severity of HAM/TSP. Leukocytes from patients with HAM/TSP were primed to respond strongly to stimulation with exogenous IFN. However, while type I IFN suppressed expression of the HTLV-1 structural protein Gag it failed to suppress the highly immunogenic viral transcriptional transactivator Tax. We conclude that over-expression of a subset of IFN-stimulated genes in chronic HTLV-1 infection does not constitute an efficient host response but instead contributes to the development of HAM/TSP.https://journals.plos.org/plospathogens/article/file?id=10.1371/journal.ppat.1002480&type=printable
spellingShingle Sonja Tattermusch
Jason A Skinner
Damien Chaussabel
Jacques Banchereau
Matthew P Berry
Finlay W McNab
Anne O'Garra
Graham P Taylor
Charles R M Bangham
Systems biology approaches reveal a specific interferon-inducible signature in HTLV-1 associated myelopathy.
PLoS Pathogens
title Systems biology approaches reveal a specific interferon-inducible signature in HTLV-1 associated myelopathy.
title_full Systems biology approaches reveal a specific interferon-inducible signature in HTLV-1 associated myelopathy.
title_fullStr Systems biology approaches reveal a specific interferon-inducible signature in HTLV-1 associated myelopathy.
title_full_unstemmed Systems biology approaches reveal a specific interferon-inducible signature in HTLV-1 associated myelopathy.
title_short Systems biology approaches reveal a specific interferon-inducible signature in HTLV-1 associated myelopathy.
title_sort systems biology approaches reveal a specific interferon inducible signature in htlv 1 associated myelopathy
url https://journals.plos.org/plospathogens/article/file?id=10.1371/journal.ppat.1002480&type=printable
work_keys_str_mv AT sonjatattermusch systemsbiologyapproachesrevealaspecificinterferoninduciblesignatureinhtlv1associatedmyelopathy
AT jasonaskinner systemsbiologyapproachesrevealaspecificinterferoninduciblesignatureinhtlv1associatedmyelopathy
AT damienchaussabel systemsbiologyapproachesrevealaspecificinterferoninduciblesignatureinhtlv1associatedmyelopathy
AT jacquesbanchereau systemsbiologyapproachesrevealaspecificinterferoninduciblesignatureinhtlv1associatedmyelopathy
AT matthewpberry systemsbiologyapproachesrevealaspecificinterferoninduciblesignatureinhtlv1associatedmyelopathy
AT finlaywmcnab systemsbiologyapproachesrevealaspecificinterferoninduciblesignatureinhtlv1associatedmyelopathy
AT anneogarra systemsbiologyapproachesrevealaspecificinterferoninduciblesignatureinhtlv1associatedmyelopathy
AT grahamptaylor systemsbiologyapproachesrevealaspecificinterferoninduciblesignatureinhtlv1associatedmyelopathy
AT charlesrmbangham systemsbiologyapproachesrevealaspecificinterferoninduciblesignatureinhtlv1associatedmyelopathy